Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
ALA-105's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for ALA-105. Showing past 6 months and next 12 months · 4 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| ALA-105 | Arovella Therapeutics | Allogeneic CLDN18.2 CAR-iNKT | Preclinical | 0 | ||||
| Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer | Liu Huang | Drug Delivery Device |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
Phase 2 |
| — |
| — |
| — |
| — |
| — |
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Thomas Jefferson University | Cancer vaccine | Phase 2 | — | — | — | — | — |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | AstraZeneca | Monoclonal antibody | Phase 2 | — | — | — | — | — |
| A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Shenyang Sunshine Pharmaceutical Co., LTD. | Other | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Jazz Pharmaceuticals | Monoclonal antibody | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | AstraZeneca | Antibody-drug conjugate | Phase 2 | — | — | — | — | — |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Daiichi Sankyo | Antibody-drug conjugate | Phase 2 | — | — | — | — | — |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Daiichi Sankyo | Antibody-drug conjugate | Phase 2 | — | — | — | — | — |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | UNICANCER | Monoclonal antibody | Phase 2 | — | — | — | — | — |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | Udai Kammula | Tumor Infiltrating Lymphocyte | Phase 2 | — | — | — | — | — |
| Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | CARsgen Therapeutics Co., Ltd. | Autologous Claudin18.2 CAR-T | PHASE1/PHASE2 | — | — | — | — | — |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | Cybrexa Therapeutics | Monoclonal antibody | PHASE1/PHASE2 | — | — | — | — | — |
| Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | CARsgen Therapeutics Co., Ltd. | Autologous Claudin18.2 CAR-T | PHASE1/PHASE2 | — | — | — | — | — |
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Emory University | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | Salubris Biotherapeutics Inc | Allogeneic CLDN18.2 CAR-iNKT | PHASE1/PHASE2 | — | — | — | — | — |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Cancer Research UK | Monoclonal antibody | PHASE1/PHASE2 | — | — | — | — | — |
| CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | Chongqing Precision Biotech Co., Ltd | Tcr Engineered T Cell | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | LigaChem Biosciences, Inc. | Antibody-drug conjugate | PHASE1/PHASE2 | — | — | — | — | — |
| Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Bispecific Other | PHASE1/PHASE2 | — | — | — | — | — |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Sensei Biotherapeutics, Inc. | Monoclonal antibody | PHASE1/PHASE2 | — | — | — | — | — |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | National Cancer Institute (NCI) | Tcr Engineered T Cell | PHASE1/PHASE2 | — | — | — | — | — |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phanes Therapeutics | Monoclonal antibody | PHASE1/PHASE2 | — | — | — | — | — |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | EMD Serono Research & Development Institute, Inc. | Antibody-drug conjugate | PHASE1/PHASE2 | — | — | — | — | — |
| A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Bristol-Myers Squibb | Bispecific Other | PHASE1/PHASE2 | — | — | — | — | — |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | ModeX Therapeutics, An OPKO Health Company | Bispecific Other | PHASE1/PHASE2 | — | — | — | — | — |
| Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | BigHat Biosciences, Inc. | Allogeneic CLDN18.2 CAR-iNKT | PHASE1/PHASE2 | — | — | — | — | — |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Nk Cell Therapy | PHASE1/PHASE2 | — | — | — | — | — |
| GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites | Kyushu University | Allogeneic CLDN18.2 CAR-iNKT | PHASE1/PHASE2 | — | — | — | — | — |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Astellas Pharma Global Development, Inc. | Other | PHASE1/PHASE2 | — | — | — | — | — |
| Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | Second Affiliated Hospital of Guangzhou Medical University | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |
| A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Cancer Research UK | Allogeneic CLDN18.2 CAR-iNKT | PHASE1/PHASE2 | — | — | — | — | — |
| Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | Shanghai Public Health Clinical Center | Allogeneic Cell Therapy Other | PHASE1/PHASE2 | — | — | — | — | — |